title: Venlafaxine and mirtazapine treatment lowers serum concentrations of dehydroepiandrosterone-sulfate in depressed patients remitting during the course of treatment.
abstract: OBJECTIVE
  The adrenal androgen dehydroepiandrosterone-sulfate (DHEA-S) seems to be involved in the pathophysiology of depression, although its precise role in the etiology and remission of depression remains unclear. In the present study we intended to examine possible differential effects of venlafaxine and mirtazapine in a randomised open trial with regard to DHEA-S serum concentrations in patients suffering from major depressive episode compared to healthy controls.
  
  
  METHODS
  We assessed DHEA-S concentrations both at baseline and after a 4-week treatment period in 70 depressed patients (n=33 for venlafaxine and n=37 for mirtazapine) and 33 matched healthy controls.
  
  
  RESULTS
  We describe the decrease of DHEA-S levels in depressive patients who remitted after treatment with both venlafaxine or mirtazapine. Patients without remission of depression did not show a significant decline in DHEA-S concentrations.
  
  
  CONCLUSIONS
  Our results suggest an effect of treatment outcome upon DHEA-S concentrations rather than a direct drug effect. The change of plasma DHEA-S levels as a marker of treatment-response of depression warrant further investigation.
authors.affiliation: Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, J5, 68159 Mannheim, Germany. Georgios.Paslakis@zi-mannheim.de
authors.forename: Georgios
authors.initials: G
authors.lastname: Paslakis
authors.forename: Peter
authors.initials: P
authors.lastname: Luppa
authors.forename: Maria
authors.initials: M
authors.lastname: Gilles
authors.forename: Daniel
authors.initials: D
authors.lastname: Kopf
authors.forename: Bettina
authors.initials: B
authors.lastname: Hamann-Weber
authors.forename: Florian
authors.initials: F
authors.lastname: Lederbogen
authors.forename: Michael
authors.initials: M
authors.lastname: Deuschle
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000704:Analysis of Variance; D000928:Antidepressive Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003511:Cyclohexanols / Q000627:therapeutic use*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood*; D003863:Depression / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D008803:Mianserin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D012463:Saliva / Q000378:metabolism; D055502:Secondary Prevention; D012737:Sex Factors; D000069470:Venlafaxine Hydrochloride
chemical_list: D000928:Antidepressive Agents; D003511:Cyclohexanols; D008803:Mianserin; D019314:Dehydroepiandrosterone Sulfate; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine; D006854:Hydrocortisone